Skip to main content
Scythene
← Back to all posts

November 19, 2026 · Nelson Marques, RD, CSSD

Ginkgo Biloba: 24% Flavonoid Glycosides / 6% Terpene Lactones or It Is Not the EGb 761 the Studies Used

The ginkgo aisle sells a 120 mg front-label number that hides whether the capsule carries the 24-6-standardized leaf extract the clinical literature actually ran on or a powdered-leaf fill that delivers roughly a thirtieth of the flavonoid-glycoside dose and almost none of the terpene-lactone fraction. Nearly every published positive ginkgo trial for cognitive and vascular endpoints ran on one specific raw material: EGb 761, a leaf extract standardized to 24 percent flavonoid glycosides and 6 percent terpene lactones with ginkgolic acids held below 5 ppm. Here is what the two fractions actually do, why the 24-6 ratio is not arbitrary, which branded extracts carry the trial literature, the proprietary-blend problem that hides the standardization, and the four-question Supplement Facts read that separates the trial-anchored material from the powdered-leaf fill.

#ginkgo#forms#standardization#labels#cognition#supplement-science

Ginkgo Biloba: 24% Flavonoid Glycosides / 6% Terpene Lactones or It Is Not the EGb 761 the Studies Used

Walk the brain-health or cognitive-support aisle and the ginkgo row reads like a single ingredient. Every bottle lists a number — 60 mg, 120 mg, 240 mg — and the buyer compares by the milligram number on the front label. The category sits on two structurally different ingredients that the milligram number treats as interchangeable and the clinical-trial literature does not.

The published human literature on Ginkgo biloba for cognitive endpoints, peripheral vascular endpoints, and age-related cognitive-decline outcomes runs almost entirely on one specific raw material: a leaf extract standardized to 24 percent flavonoid glycosides and 6 percent terpene lactones, with ginkgolic acids held below 5 parts per million, dosed at 120 to 240 mg per day. The material is EGb 761, the Schwabe-patented specification, and SchwabeStandardized, Tebonin, Rökan, Tanakan, Ginkoba, and a handful of other branded extracts are the materials the GEM (Ginkgo Evaluation of Memory) trials, the DeKosky 2008 and Snitz 2009 reports, the GuidAge trial, and the broader European cognitive-decline literature actually used.

The powdered-leaf capsule that says "Ginkgo Biloba 120 mg" on the front label and nothing else on the back is a different ingredient. Powdered dried leaf carries roughly 0.5 to 1 percent flavonoid glycosides by weight and well under 0.1 percent terpene lactones. Two capsules of the same 120 mg front-label number — one carrying 24-6 standardization, the other carrying raw-leaf powder — differ in the flavonoid-glycoside dose by a factor of twenty-four to forty-eight and in the terpene-lactone dose by a factor of sixty or more.

This is the same pattern that runs through the clinically studied ingredient versus clinically studied dose problem, the proprietary blends underdosing problem, and the 60-second supplement label read: the front-label number is not the same thing as the active-fraction dose the body actually sees.

What the Two Active Fractions Actually Are

Ginkgo biloba leaf contains a mixture of flavonoid glycosides (kaempferol, quercetin, and isorhamnetin glycosides), terpene lactones (ginkgolides A, B, C, J and bilobalide), long-chain phenolic acids (the ginkgolic acid family), proanthocyanidins, and a water-soluble polysaccharide fraction. The pharmacologically active fractions — the ones the published mechanisms-of-action work pins the outcomes on — are the flavonoid glycosides and the terpene lactones, not the water-soluble fraction or the fiber.

The flavonoid glycosides do antioxidant work and membrane-stabilization work at the vascular endothelium and the neuron. The published mechanisms include nitric-oxide-synthase modulation, free-radical scavenging at the lipid bilayer, and inhibition of oxidized-LDL-driven endothelial dysfunction. The 24 percent target was chosen because it is the flavonoid-glycoside concentration that reliably delivers the dose range the pharmacokinetic work shows crosses into clinically meaningful plasma exposure at 120-to-240 mg total extract per day.

The terpene lactones do a different job. The ginkgolides, especially ginkgolide B, are platelet-activating-factor (PAF) antagonists — they bind the PAF receptor on platelets, vascular endothelium, and neurons and block the PAF-driven inflammatory and aggregation cascade. Bilobalide, the other terpene lactone, has documented GABAergic and mitochondrial-membrane-stabilization activity in the preclinical literature. The 6 percent target delivers the ginkgolide B dose range the pharmacokinetic work ties to the mechanism-of-action endpoints.

The 24-6 ratio is not arbitrary and it is not aesthetic. It is the specification that delivers both fractions at the doses the clinical-trial literature ran on. An extract standardized to only one of the two fractions, or to either fraction at a lower percentage, is not EGb 761 and does not carry the trial-anchored evidence.

The Ginkgolic Acid Problem the Standardization Also Solves

The ginkgolic acids are the allergenic fraction of the raw leaf. Chemically similar to the urushiol oils in poison ivy, the ginkgolic acid family can trigger contact dermatitis, allergic reactions, and in higher chronic exposures the long-chain phenols have documented mutagenic and neurotoxic signals in the preclinical literature. Raw ginkgo leaf runs 1 to 2 percent ginkgolic acids by weight — enough that a 240 mg per day leaf-powder dose delivers 2.4 to 4.8 mg of the allergenic fraction daily.

The EGb 761 specification requires ginkgolic acids held below 5 parts per million. That is a 2,000-to-4,000-fold reduction against raw-leaf weight and the specification the European Medicines Agency uses as the reference for ginkgo quality. Products that do not disclose their ginkgolic acid content are not held to that spec. A standardized extract that names 24 percent flavonoid glycosides and 6 percent terpene lactones but does not name the ginkgolic acid specification is only partly matching EGb 761; a well-run manufacturer discloses all three numbers on the Supplement Facts panel or the product page.

The IU-Free Label Trap

Unlike vitamin A or vitamin D, ginkgo has no established daily value, no IU equivalent, and no required-label unit beyond the milligram weight of the capsule contents. The label is required to disclose how much of what is in the capsule but is not required to disclose the standardization in plain terms. The compliant minimum is often a one-line entry on the Supplement Facts panel that reads:

Ginkgo Biloba Extract (leaf) 120 mg

That line is compliant whether the extract is 24-6 standardized or 2-0.3 standardized or is raw leaf powder. Unless the line continues with "(standardized to 24 percent flavonoid glycosides and 6 percent terpene lactones)" or "(EGb 761)" or names a specific branded raw material (Tebonin, SchwabeStandardized, Rökan, Tanakan), the label has disclosed nothing that separates the trial-anchored material from the under-dosed fill.

The trial-anchored brands disclose. The commodity-shelf brands do not. A supplement-literate buyer treats the absence of the standardization as the answer — if it were 24-6, the label would say so, because that is the specification the retailer pays a premium for and the brand uses as a selling point.

What the Branded Raw Materials Carry the Trial Literature

Four branded raw materials carry essentially all of the published positive ginkgo literature on cognitive and vascular endpoints:

EGb 761 (Schwabe, Germany). The reference material. Twenty-four percent flavonoid glycosides, six percent terpene lactones (with ginkgolides A plus B plus C at approximately 3.1 percent and bilobalide at approximately 2.9 percent), ginkgolic acids below 5 ppm. This is the material sold as Tebonin, Rökan, Tanakan, Ginkoba, and under license to a number of brand partners. The GEM trials, the DeKosky 2008 report, the GuidAge trial, and most of the European cognitive-decline literature ran on EGb 761.

LI 1370 (Lichtwer Pharma, Germany). Historically marketed as Ginkai. Twenty-five percent flavonoid glycosides, six percent terpene lactones, ginkgolic acids below 1 ppm. A smaller but published literature on peripheral vascular endpoints.

GK501 (Indena, Italy). Twenty-four percent flavonoid glycosides, six percent terpene lactones. Used in several Italian and European trials on vascular cognitive outcomes.

Phytosome-complexed ginkgo extract (Indena, Italy; "Ginkgoselect Phytosome"). A phospholipid-complexed delivery system over a 24-6 standardized base extract. Pharmacokinetic work suggests higher plasma exposure per milligram against the free extract, and a smaller but growing published outcome literature.

A product that names one of those branded raw materials in the Supplement Facts panel or on the product page is a product that carries the trial-anchored evidence. A product that says "Ginkgo Biloba Leaf Extract 120 mg" with no standardization line and no branded material named is a product that does not.

The Proprietary-Blend Problem

A sizable slice of the brain-health and cognitive-support category hides ginkgo inside a proprietary blend. The label reads something like:

Brain Support Blend 500 mg: Ginkgo Biloba Leaf Extract, Bacopa monnieri, Phosphatidylserine, L-Theanine

That line is compliant. It discloses the total blend weight (500 mg) and the ingredient identities but is not required to disclose the per-ingredient weight. The ginkgo fraction of a 500 mg blend built around four ingredients is almost always well below the 120 mg floor the trial literature ran on, and the standardization of the ginkgo fraction is almost never disclosed. A 500 mg blend might carry 40 mg of ginkgo leaf powder; same front-label category, roughly one one-hundredth of the EGb 761 active-fraction dose.

A reader of this blog's proprietary blends underdosing post treats a blended ginkgo product as an under-dosed ginkgo product until the label discloses otherwise. The absence of the per-ingredient weight is the answer.

The Four-Question Supplement Facts Read

A supplement-literate buyer asks four questions of any ginkgo product before buying it.

One: does the Supplement Facts panel name the standardization? Look for "24% flavonoid glycosides" (or sometimes written as "flavone glycosides" or "ginkgo flavonglycosides") and "6% terpene lactones" (or "terpenoid lactones" or "ginkgolides and bilobalide"). If both percentages are not on the label, the product is not EGb 761-grade regardless of what the marketing copy says.

Two: does the label name the branded raw material? EGb 761, Tebonin, SchwabeStandardized, LI 1370, GK501, or Ginkgoselect Phytosome are the names that carry the published literature. A named branded material is a stronger signal than a 24-6 claim without a branded material, because the named material carries the documented ginkgolic-acid specification and the manufacturing controls behind the trial literature.

Three: is the ginkgolic acid content disclosed? The EGb 761 specification is below 5 ppm. A product that discloses "ginkgolic acids below 5 ppm" or "ginkgolic acids below 1 ppm" has committed to the safety specification the European Medicines Agency uses as the reference. A product that does not disclose the ginkgolic acid content has not, and in the raw-leaf-powder case the unlabeled ginkgolic acid exposure is a real consideration for chronic daily dosing.

Four: is the per-serving dose 120 to 240 mg of the standardized extract, not the total blend weight? The trial literature ran on 120 to 240 mg per day of EGb 761 or its equivalents, split as a single dose or 60-to-120 mg twice daily. A product delivering 40 mg of unstandardized ginkgo inside a blend, even if the blend total is 500 mg, is not delivering the clinically studied dose.

The Bottom Line

The ginkgo category is built on a specification — EGb 761 at 24 percent flavonoid glycosides, 6 percent terpene lactones, and ginkgolic acids below 5 ppm — and the published outcome literature does not generalize to the raw-leaf capsule carrying the same milligram number on the front label. The branded raw materials disclose the specification because the specification is the product. The commodity-shelf brands do not disclose because they do not have it to disclose. The buyer who learns to read the four questions above stops comparing ginkgo products by the front-label milligram number and starts comparing them by the only numbers that actually read the active-fraction dose the trial literature ran on.

That is the Scythene read on ginkgo, and it is the same read we run on every ingredient we touch. The specification is the product. The milligram number on the front of a bottle is marketing. The Supplement Facts panel is where the two meet, and the buyer who learns to read it is the buyer who stops overpaying for underdosed fill.

SUBSCRIBE

Get more like this.

Evidence-based writing on supplements, performance nutrition, and the research behind what actually works. No spam, no daily emails — just the good stuff.

Written by Nelson Marques, RD, CSSD — a registered dietitian and board certified specialist in sports dietetics with 10 years in performance nutrition. Founder of Scythene Supplements.

More about Nelson →